Mylan Nv Ord Shs (MYL) 44.53 $MYL
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 26.32 (-1.61), GBT: 24.15 (+2.00), AXLL: 32.56 (+6.75), C: 43.90 (-1.11), MYL: 44.53 (-1.23), WFC: 48.34 (-0.80), MFRM: 29.40 (-4.18), HRB: 24.23 (+2.69)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.53 (-1.23)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.53 (-1.23)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 44.53 (-1.23)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 91.49 (-1.00), FCX: 10.36 (-0.54), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), MYL: 44.53 (-1.23), BA: 131.14 (-1.96), SLB: 78.53 (-1.43), AA: 9.49 (-0.35), LYB: 80.47 (+0.55), RIG: 10.75 (-0.72), KITE: 51.30 (-2.12), CF: 29.23 (-0.56), CHK: 4.42 (-0.46), EOG: 81.56 (-3.02), CVX: 101.98 (-0.83), ECL: 120.25 (-0.54)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Fri Jun 03, 1:00PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.
MYL: 44.53 (-1.23)
Mylan Launches Generic Cleocin® Solution
PR Newswire - Fri Jun 03, 9:56AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.(1)
MYL: 44.53 (-1.23)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 44.53 (-1.23), CELGZ: 1.46 (-0.04)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 44.53 (-1.23), GSK: 40.93 (-1.13)
Look for Shares of Mylan to Potentially Pullback after Yesterday's 2.58% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:29PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Watch for Mylan to Potentially Pullback After Gaining 2.58% Yesterday
Comtex SmarTrend(R) - Wed Jun 01, 12:28PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Mylan Launches First Generic of Doxycycline Hyclate Delayed-Release Tablets, 50 mg
PR Newswire - Wed Jun 01, 10:42AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Doxycycline Hyclate Delayed-Release (DR) Tablets USP, 50 mg, a generic version of Mayne's Doxteric, which is being marketed as Doryx®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) and was awarded 180 days of marketing exclusivity for this product. Mylan also recently announced the launch of the 200 mg strength of this product with 180 days of exclusivity. Doxycycline Hyclate DR Tablets are a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.
MYL: 44.53 (-1.23)
Mylan Launches First Generic of Nuvigil® Tablets
PR Newswire - Wed Jun 01, 9:15AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's Nuvigil®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) and was awarded 180 days of marketing exclusivity for these strengths. Armodafinil Tablets are used to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, narcolepsy or shift-work disorder.
MYL: 44.53 (-1.23)
Mylan Announces Pricing of Senior Notes
PR Newswire - Tue May 31, 4:24PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $6.5 billion aggregate principal amount of senior notes, comprised of $1.0 billion aggregate principal amount of 2.50% senior notes due 2019 at an issue price of 99.888%, $2.25 billion aggregate principal amount of 3.15% senior notes due 2021 at an issue price of 99.884%, $2.25 billion aggregate principal amount of 3.95% senior notes due 2026 at an issue price of 99.231% and $1.0 billion aggregate principal amount of 5.25% senior notes due 2046 at an issue price of 99.984%. Mylan intends to use the net proceeds from the offering of notes to finance its previously announced public offer (the "Offer"
to acquire all of the outstanding shares of Meda AB (publ.) (the "Meda Acquisition", to repay, prepay, redeem or otherwise refinance its or any of its subsidiaries' indebtedness (including that of Meda and its subsidiaries) (the "Refinancing" and to pay costs associated with the Meda Acquisition and the Refinancing, including non-periodic fees, costs and expenses, stamp registration and other taxes. Upon completion of the offering of the notes, Mylan intends to reduce the commitments under its Bridge Credit Agreement, dated as of Feb. 10, 2016, in an amount equal to the aggregate net proceeds from the offering of the notes. Subject to customary closing conditions, the sale of the notes is expected to close on or about June 9, 2016.
MYL: 44.53 (-1.23)
Mylan Set to Possibly Pullback After Yesterday's Rally of 1.56%
Comtex SmarTrend(R) - Fri May 27, 12:36PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.89 to a high of $43.84. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $43.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
After Yesterday's Rally of 1.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 27, 12:35PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.89 to a high of $43.84. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $43.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Learn how to target a 20% return on The Home Depot Inc, or get option-trade ideas on Whole Foods Market, Mylan, FireEye and Sysco Corporation or any stock you choose
PR Newswire - Fri May 27, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for HD, WFM, MYL, FEYE and SYY.
WFM: 34.31 (-0.47), HD: 128.83 (-0.47), FEYE: 15.81 (-0.77), SYY: 48.78 (-0.22), MYL: 44.53 (-1.23)
Mylan to Present at Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu May 26, 10:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) a leading global pharmaceutical company, today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, CA. The presentation is scheduled to begin at 2:40 p.m. PT / 5:40 p.m. ET.
MYL: 44.53 (-1.23)
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 26.32 (-1.61), GBT: 24.15 (+2.00), AXLL: 32.56 (+6.75), C: 43.90 (-1.11), MYL: 44.53 (-1.23), WFC: 48.34 (-0.80), MFRM: 29.40 (-4.18), HRB: 24.23 (+2.69)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.53 (-1.23)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.53 (-1.23)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 44.53 (-1.23)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 91.49 (-1.00), FCX: 10.36 (-0.54), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), MYL: 44.53 (-1.23), BA: 131.14 (-1.96), SLB: 78.53 (-1.43), AA: 9.49 (-0.35), LYB: 80.47 (+0.55), RIG: 10.75 (-0.72), KITE: 51.30 (-2.12), CF: 29.23 (-0.56), CHK: 4.42 (-0.46), EOG: 81.56 (-3.02), CVX: 101.98 (-0.83), ECL: 120.25 (-0.54)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Fri Jun 03, 1:00PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.
MYL: 44.53 (-1.23)
Mylan Launches Generic Cleocin® Solution
PR Newswire - Fri Jun 03, 9:56AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.(1)
MYL: 44.53 (-1.23)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 44.53 (-1.23), CELGZ: 1.46 (-0.04)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 44.53 (-1.23), GSK: 40.93 (-1.13)
Look for Shares of Mylan to Potentially Pullback after Yesterday's 2.58% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:29PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Watch for Mylan to Potentially Pullback After Gaining 2.58% Yesterday
Comtex SmarTrend(R) - Wed Jun 01, 12:28PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Mylan Launches First Generic of Doxycycline Hyclate Delayed-Release Tablets, 50 mg
PR Newswire - Wed Jun 01, 10:42AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Doxycycline Hyclate Delayed-Release (DR) Tablets USP, 50 mg, a generic version of Mayne's Doxteric, which is being marketed as Doryx®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) and was awarded 180 days of marketing exclusivity for this product. Mylan also recently announced the launch of the 200 mg strength of this product with 180 days of exclusivity. Doxycycline Hyclate DR Tablets are a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.
MYL: 44.53 (-1.23)
Mylan Launches First Generic of Nuvigil® Tablets
PR Newswire - Wed Jun 01, 9:15AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's Nuvigil®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) and was awarded 180 days of marketing exclusivity for these strengths. Armodafinil Tablets are used to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, narcolepsy or shift-work disorder.
MYL: 44.53 (-1.23)
Mylan Announces Pricing of Senior Notes
PR Newswire - Tue May 31, 4:24PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $6.5 billion aggregate principal amount of senior notes, comprised of $1.0 billion aggregate principal amount of 2.50% senior notes due 2019 at an issue price of 99.888%, $2.25 billion aggregate principal amount of 3.15% senior notes due 2021 at an issue price of 99.884%, $2.25 billion aggregate principal amount of 3.95% senior notes due 2026 at an issue price of 99.231% and $1.0 billion aggregate principal amount of 5.25% senior notes due 2046 at an issue price of 99.984%. Mylan intends to use the net proceeds from the offering of notes to finance its previously announced public offer (the "Offer"
to acquire all of the outstanding shares of Meda AB (publ.) (the "Meda Acquisition", to repay, prepay, redeem or otherwise refinance its or any of its subsidiaries' indebtedness (including that of Meda and its subsidiaries) (the "Refinancing" and to pay costs associated with the Meda Acquisition and the Refinancing, including non-periodic fees, costs and expenses, stamp registration and other taxes. Upon completion of the offering of the notes, Mylan intends to reduce the commitments under its Bridge Credit Agreement, dated as of Feb. 10, 2016, in an amount equal to the aggregate net proceeds from the offering of the notes. Subject to customary closing conditions, the sale of the notes is expected to close on or about June 9, 2016. MYL: 44.53 (-1.23)
Mylan Set to Possibly Pullback After Yesterday's Rally of 1.56%
Comtex SmarTrend(R) - Fri May 27, 12:36PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.89 to a high of $43.84. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $43.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
After Yesterday's Rally of 1.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 27, 12:35PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.89 to a high of $43.84. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $43.00 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.53 (-1.23)
Learn how to target a 20% return on The Home Depot Inc, or get option-trade ideas on Whole Foods Market, Mylan, FireEye and Sysco Corporation or any stock you choose
PR Newswire - Fri May 27, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for HD, WFM, MYL, FEYE and SYY.
WFM: 34.31 (-0.47), HD: 128.83 (-0.47), FEYE: 15.81 (-0.77), SYY: 48.78 (-0.22), MYL: 44.53 (-1.23)
Mylan to Present at Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu May 26, 10:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) a leading global pharmaceutical company, today announced that the Company will present at the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, CA. The presentation is scheduled to begin at 2:40 p.m. PT / 5:40 p.m. ET.
MYL: 44.53 (-1.23)
